MAXCYTE, INC. - 8-K Filing
MaxCyte, Inc. enters agreement to acquire Akron BioProducts LLC for $105 million in cash, 20.6 million shares of common stock, and $20 million in deferred payments. (Items: 1.01 Entry into a Material Definitive Agreement, 2.02 Results of Operations and Financial Condition, 3.02 Unregistered Sales of Equity Securities, 7.01 Regulation FD Disclosure)
Tickers: $MXCT
Read the full article at SEC EDGAR
Part of the story Imunon, Inc. - 8-K Filing (38 articles)